Celularity, Inc. logo

Celularity, Inc.

Transforming lives by harnessing the power_of placenta-derived cells and tissues to amplify the bodys ability to fight disease and regenerate itself Celularity is using stem cells derived from the placenta to create transformative therapeutic options across immuno-oncology, autoimmune and degenerative disease, and functional regeneration. Celularity has over a dozen pre-clinical trials and Investigational New Drug applications (IND) in progress.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.celularity.com
Disease Focus
STOCK CODENon Listed
Address
7 Powderhorn Drive, NJ 07059
Warren
United States
Email
Contact Number
+1 908-673-9000

Celularity is using stem cells derived from the placenta to create transformative therapeutic options across immuno-oncology, autoimmune and degenerative disease, and functional regeneration. Celularity has over a dozen pre-clinical trials and Investigational New Drug applications (IND) in progress.

Celularity, was founded by stem cell pioneer Robert Hariri. Celularity has assembled an industry-leading intellectual property portfolio of more than 800 issued patents, which attain a dominating position around placental-derived stem and progenitor cells.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/celularity” connections=”true” suffix=””]

Celularity is the only company to use an allogenic placental platform and stem cells derived from the placenta are intrinsically safe, and can be taken from any placenta and injected into any human without the risk of rejection. Its Proprietary Technologies include: cell expension/differentiation, next-generation CAR, allogeneic Çoff-the-shelf NK and T-cell therapy, autologous T-cell therapy, G-MABë library, and gene editing platform to engineer NK & T cells.

Celularity is accelerating the development of cell and tissue regenerative products to address unmet medical needs, by combining synergistic assets from Celgene, United Therapeutics, Sorrento Therapeutics, and Human Longevity Inc.

Celularity, was formed with $250M in funding with contributions from Celgene, United Therapeutics, Sorrento Therapeutics, Human Longevity, Inc., Genting Group, the Dreyfus Family Office, Section 32, and Heritage Group.